Experimental brain tumor injection shows promise in early trial
NCT ID NCT07501559
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This study tests a new drug called JL15003, given as an injection directly into the brain tumor or the space left after surgery. It is for adults with recurrent glioblastoma, an aggressive brain cancer that has come back after standard treatment. The trial aims to see if the drug is safe and whether it can help control the tumor or extend survival.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
JL15003 injection (a biologic drug given directly into the tumor or the cavity left after tumor removal)
What this could lead to
If it works, this could offer a new treatment option for people with recurrent glioblastoma, potentially extending survival or controlling the disease.
What could go wrong
This is an early-phase trial with only 40 participants, so results may not apply to everyone. The treatment is experimental and may cause side effects or fail to improve outcomes.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RECURRENT GLIOBLASTOMA MULTIFORME(GBM) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Huashan Hospital, Shanghai Medical College, Fudan University & Beijing TianTan Hospital,Capital Medical University
RECRUITINGShanghai, China
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••